Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04675723 · ClinicalTrials.gov registry record
The Role of Mucosal Microbiome in Recurrence of Clostridioides Difficile Infection
A clinical trial of Clostridioides Difficile Infection, sponsored by Mayo Clinic.
- Completed
- Registry status
- 52
- Enrollment target
- 1
- Study location
NCT04675723 is a study of Clostridioides Difficile Infection that has completed, run by Mayo Clinic. The registered enrollment target is 52 participants, below the 417-participant average among 6 other Clostridioides Difficile Infection trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04675723, a study of Clostridioides Difficile Infection, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is being done to identify types of bacteria associated with the lining of the large intestine in people who have recently been treated for C. difficile infection to determine if there are features associated with recurrent disease.
Conditions Studied
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2019-09-23 |
| Est. Completion | 2022-05-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04675723
The ClinicalTrials.gov registry entry for NCT04675723 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 417-participant average among 6 other Clostridioides Difficile Infection trials with a reported enrollment target (88% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Clostridioides Difficile Infection appearing as the primary indexed condition, and to 0 interventions.
NCT04675723 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT04675723 about?
NCT04675723 is a clinical study titled "The Role of Mucosal Microbiome in Recurrence of Clostridioides Difficile Infection". The study is being done to identify types of bacteria associated with the lining of the large intestine in people who have recently been treated for C. difficile infection to determine if there are features associated with recurrent disease.
What is the current status of trial NCT04675723?
This trial is currently completed. The enrollment target is 52 participants. The study started on 2019-09-23. Estimated completion is 2022-05-05.
What conditions does trial NCT04675723 study?
This clinical trial studies the following conditions: Clostridioides Difficile Infection.
Who is sponsoring clinical trial NCT04675723?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04675723 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clostridioides Difficile Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
LMN-201 for Prevention of C. Difficile Infection Recurrence
RECRUITING · Phase 2
-
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
RECRUITING · Phase 2
-
Evaluation of GeoHAI Implementation
RECRUITING · NA
-
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
RECRUITING · Phase 3
-
Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)
RECRUITING · Phase 2
-
Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.